title: Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
abstract: OBJECTIVE
  Coronary artery bypass graft surgery remains associated with significant postoperative cardiovascular morbidity and mortality in high-risk patients. MC-1 (pyridoxal-5'-phosphate monohydrate) inhibits purinergic receptors and intracellular influx of Ca2+, thereby reducing cellular injury during experimental ischemia and reperfusion. The MEND-CABG trial tested the hypothesis that MC-1 reduces cardiovascular morbidity and mortality after coronary artery bypass graft.
  
  
  METHODS
  In a phase 2, double-blinded, placebo-controlled study, 901 patients scheduled for coronary artery bypass graft surgery with cardiopulmonary bypass and at high risk for subsequent cardiac or neurologic complications were randomly assigned to receive oral MC-1 (250 mg or 750 mg/d once daily) or placebo beginning 3 to 10 hours prior to surgery and continued to postoperative day 30.
  
  
  RESULTS
  At 30 days, MC-1 250 mg (compared with placebo) reduced the composite of death, nonfatal cerebral infarction, and nonfatal myocardial infarction by 14.0% (P = .3124) with peak creatinine kinase-myocardial band > or =50 ng/mL (prespecified primary end point); 32.3% (P = .0349) with peak creatinine kinase-myocardial band > or =70 ng/mL; and 37.2% (P = .0283) with peak creatinine kinase-myocardial band > or =100 ng/mL. Myocardial infarctions with peak creatinine kinase-myocardial band> or =100 ng/mL were reduced by 47.2% in the MC-1 250-mg group versus placebo (P = .0083). Greater efficacy was demonstrated with 250 mg than with the 750-mg dose of MC-1.
  
  
  CONCLUSIONS
  In high-risk patients undergoing coronary artery bypass graft, treatment with MC-1 did not significantly affect the prespecified primary end point but was associated with a significant reduction in perioperative myocardial infarction with creatinine kinase-myocardial band > or =100 ng/mL. A larger, well-powered trial is needed to evaluate the cardioprotective effects of MC-1.
authors.affiliation: Montreal Heart Institute, Montreal, Canada. jean-claude.tardif@icm-mhi.org
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Tardif
authors.forename: Michel
authors.initials: M
authors.lastname: Carrier
authors.forename: David E
authors.initials: DE
authors.lastname: Kandzari
authors.forename: Robert
authors.initials: R
authors.lastname: Emery
authors.forename: Robert
authors.initials: R
authors.lastname: Cote
authors.forename: Therese
authors.initials: T
authors.lastname: Heinonen
authors.forename: Marjorie
authors.initials: M
authors.lastname: Zettler
authors.forename: Vic
authors.initials: V
authors.lastname: Hasselblad
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Guertin
authors.forename: Robert A
authors.initials: RA
authors.lastname: Harrington
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D002170:Canada; D002315:Cardiopulmonary Bypass; D002318:Cardiovascular Diseases / Q000401:mortality / Q000601:surgery*; D016009:Chi-Square Distribution; D001026:Coronary Artery Bypass / Q000009:adverse effects; D052279:Creatine Kinase, MB Form / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control*; D011732:Pyridoxal Phosphate / Q000008:administration & dosage / Q000627:therapeutic use*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014481:United States
chemical_list: D011732:Pyridoxal Phosphate; D052279:Creatine Kinase, MB Form